Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Mullard

Showing results (11-20 of 681) with videos related to

Pageof 69
Sort By:
Nature Reviews. Drug Discovery|June 23, 2023
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objectionsAsher Mullard
Nature Reviews. Drug Discovery|June 15, 2023
A cancer drug wish listAsher Mullard
Nature Reviews. Drug Discovery|September 12, 2020
Karen AkinsanyaAsher Mullard
Nature Reviews. Drug Discovery|March 24, 2020
Stemming the tide of drug resistance in cancerAsher Mullard
Nature Reviews. Drug Discovery|October 6, 2020
ADCs inspire large pharma investmentsAsher Mullard
Nature Reviews. Drug Discovery|October 13, 2020
Fragment-based screening sees the lightAsher Mullard
Nature Reviews. Drug Discovery|June 11, 2021
FDA approval for Biogen's aducanumab sparks Alzheimer disease firestormAsher Mullard
Nature Reviews. Drug Discovery|July 9, 2021
Immuno-oncology target TIGIT attracts a new contenderAsher Mullard
Nature Reviews. Drug Discovery|July 17, 2023
Claudin-18.2 attracts the cancer crowdAsher Mullard
Nature Reviews. Drug Discovery|August 4, 2023
The high, and redundant, cost of failure in cancer drug developmentAsher Mullard
Pageof 69

Showing results (11-20 of 681) with videos related to

Sort By:
Pageof 69
Nature Reviews. Drug Discovery|June 23, 2023
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objectionsAsher Mullard
Nature Reviews. Drug Discovery|June 15, 2023
A cancer drug wish listAsher Mullard
Nature Reviews. Drug Discovery|September 12, 2020
Karen AkinsanyaAsher Mullard
Nature Reviews. Drug Discovery|March 24, 2020
Stemming the tide of drug resistance in cancerAsher Mullard
Nature Reviews. Drug Discovery|October 6, 2020
ADCs inspire large pharma investmentsAsher Mullard
Nature Reviews. Drug Discovery|October 13, 2020
Fragment-based screening sees the lightAsher Mullard
Nature Reviews. Drug Discovery|June 11, 2021
FDA approval for Biogen's aducanumab sparks Alzheimer disease firestormAsher Mullard
Nature Reviews. Drug Discovery|July 9, 2021
Immuno-oncology target TIGIT attracts a new contenderAsher Mullard
Nature Reviews. Drug Discovery|July 17, 2023
Claudin-18.2 attracts the cancer crowdAsher Mullard
Nature Reviews. Drug Discovery|August 4, 2023
The high, and redundant, cost of failure in cancer drug developmentAsher Mullard
Pageof 69